凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06821 凯莱英

未开盘 04-09 16:08:13

98.350

+1.850

+1.92%

最高101.900	最低96.000	成交量104.79万
今开96.000	昨收96.500	日振幅6.11%
总市值355.04亿	流通市值27.10亿	总股本3.61亿
成交额1.04亿	换手率3.80%	流通股本2,755万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06821","market":"HK","secType":"STK","nameCN":"凯莱英","latestPrice":98.35,"timestamp":1775722093008,"preClose":96.5,"halted":0,"volume":1047920,"delay":0,"changeRate":0.019170984455958492,"floatShares":27553260,"shares":361000000,"eps":3.626902019774675,"marketStatus":"未开盘","change":1.85,"latestTime":"04-09 16:08:13","open":96,"high":101.9,"low":96,"amount":103627032,"amplitude":0.06114,"askPrice":98.4,"askSize":4300,"bidPrice":98.35,"bidSize":14100,"shortable":3,"etf":0,"ttmEps":3.626902019774675,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775784600000},"marketStatusCode":0,"adr":0,"listingDate":1639065600000,"exchange":"SEHK","adjPreClose":96.5,"dividendRate":0.012214,"openAndCloseTimeList":[[1775698200000,1775707200000],[1775710800000,1775721600000]],"volumeRatio":0.570454,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"002821","market":"SZ","secType":"STK","nameCN":"凯莱英","latestPrice":121.25,"timestamp":1775718000000,"preClose":118.72,"halted":0,"volume":15146500,"delay":0,"premium":"-29.33"}},"requestUrl":"/m/hq/s/06821","defaultTab":"news","newsList":[{"id":"2625945941","title":"Norges Bank减持凯莱英(06821)26.32万股 每股作价约104.64港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2625945941","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625945941?lang=zh_cn&edition=full","pubTime":"2026-04-08 18:59","pubTimestamp":1775645977,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，4月2日，Norges Bank减持凯莱英(06821)26.32万股，每股作价104.6389港元，总金额约为2754.1万港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260408/20260408185955_73298.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260408/20260408185955_73298.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","LU1328615791.USD","06821","BK0239","EWH","BK0132","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625640986","title":"毛利率创上市来新低，凯莱英小分子业务仍处于调整阶段，多肽业务产能正爬坡","url":"https://stock-news.laohu8.com/highlight/detail?id=2625640986","media":"深圳商报·读创","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625640986?lang=zh_cn&edition=full","pubTime":"2026-04-07 10:20","pubTimestamp":1775528416,"startTime":"0","endTime":"0","summary":"近日，凯莱英（002821）在业绩说明会上公司展望2026年时表示，营业收入增长预计19%~22%，就分业务板块而言，小分子业务目前仍处于调整阶段，商业化项目表现可圈可点，整体能够保持稳健态势。新兴业务有望持续保持高增长态势，两个大分子业务板块业绩预计将表现更为突出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604073696240266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK0239","06821","LU1328615791.USD","002821","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624151698","title":"凯莱英：展望2026年营业收入增长预计19%-22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624151698","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624151698?lang=zh_cn&edition=full","pubTime":"2026-04-04 09:02","pubTimestamp":1775264536,"startTime":"0","endTime":"0","summary":"南方财经4月4日电，凯莱英4月3日在业绩说明会表示，公司展望2026年营业收入增长预计19%-22%，分业务板块展望2026年：小分子业务目前仍处于调整阶段，商业化项目表现可圈可点，整体能够保持稳健态势。新兴业务有望持续保持高增长态势，两个大分子业务板块业绩预计将表现更为突出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604043695524881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["002821","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624674656","title":"凯莱英（002821）披露股票交易异常波动公告，4月3日股价下跌3.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624674656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624674656?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:01","pubTimestamp":1775206892,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，凯莱英报收于122.06元，较前一交易日下跌3.62%，最新总市值为440.48亿元。该股当日开盘125.01元，最高125.5元，最低121.35元，成交额达26.22亿元，换手率为6.72%。凯莱英于近日披露《关于公司股票交易异常波动的公告》。公告显示，公司股票于2026年3月31日和4月1日连续两个交易日内收盘价格涨幅偏离值累计超过20%，构成股票交易异常波动。公司董事会确认无应披露而未披露事项，不存在违反信息披露公平性情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300032851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06821","BK0239","002821","BK0132","LU1328615791.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111673943","title":"凯莱英更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1111673943","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111673943?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:41","pubTimestamp":1775119315,"startTime":"0","endTime":"0","summary":"凯莱英于2026年4月2日披露了截至2026年3月31日的股份变动月报表。报告期内，公司已发行股本和库藏股整体保持稳定，未发生新增发行、购回或注销活动。截至2026年3月31日，公司注册股本为人民币360,874,970元。公司于此前获股东大会通过的限制性股票计划及股权激励方案并未在本月产生实际新增发行或库藏股变动，计划下可发行股份数量维持不变。公司确认已遵守香港联交所《上市规则》的相关规定。截至本月末，凯莱英股本总数维持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9589a36a1b64e7c7d7a94166c3b09e9b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590592","title":"凯莱英最新公告：股票交易异常波动","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590592","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624590592?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:09","pubTimestamp":1775041792,"startTime":"0","endTime":"0","summary":"凯莱英公告称，公司股票在2026年3月31日、4月1日连续两个交易日内收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动。此外，公司于3月30日审议通过了2025年年度报告及利润分配预案等相关议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100036618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK1191","LU1328615791.USD","002821","BK0239","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624599484","title":"4月1日凯莱英（002821）龙虎榜数据：机构净买入5723.67万元，北向资金净买入1576.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624599484","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624599484?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:19","pubTimestamp":1775035183,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月1日公布的交易公开信息显示，凯莱英因日涨幅偏离值达到7%的前5只证券，连续三个交易日内，涨幅偏离值累计达到20%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月1日收盘，凯莱英报收于121.85元，上涨10.0%，换手率6.03%，成交量19.13万手，成交额22.37亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入5723.67万元，北向资金合计净买入1576.32万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100031581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0132","06821","LU1328615791.USD","002821","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624596505","title":"凯莱英：公司是一家全球行业领先的CDMO一站式综合解决方案提供商","url":"https://stock-news.laohu8.com/highlight/detail?id=2624596505","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624596505?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:48","pubTimestamp":1775033292,"startTime":"0","endTime":"0","summary":"证券之星消息，凯莱英04月01日在投资者关系平台上答复投资者关心的问题。公司是一家全球行业领先的CDMO一站式综合解决方案提供商，致力于全球制药工艺的技术创新和商业化应用，核心业务聚焦在法规监管要求严、供货量级大的产品阶段。相关情况请详见公司已披露的2025年度报告，感谢您的关注！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100030079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06821","002821","LU1328615791.USD","BK0239","BK1191","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624596345","title":"凯莱英：公司近年推行的降本增效措施成果显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2624596345","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624596345?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:45","pubTimestamp":1775033137,"startTime":"0","endTime":"0","summary":"证券之星消息，凯莱英(002821)04月01日在投资者关系平台上答复投资者关心的问题。投资者提问：2025年年报披露，公司本期营业收入变化率与销售费用和管理费用变化率相差24%，请问公司财务报表是否有问题？财务数据是否真实反映？凯莱英回复：尊敬的投资者，您好！公司近年推行的降本增效措施成果显著，年度报告真实反应了公司生产经营成果。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100030020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0239","002821","LU1328615791.USD","BK0132","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123415733","title":"异动解读 | AACR年会临近提振板块情绪，凯莱英盘中大涨13.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123415733","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123415733?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:44","pubTimestamp":1775022294,"startTime":"0","endTime":"0","summary":"凯莱英今日盘中股价大幅上涨13.08%，引起了市场的广泛关注。消息面上，逾百家药企即将亮相美国癌症研究协会（AACR）年会，这一事件提振了整体生物医药板块的投资情绪，恒生生物医药指数也随之上涨。作为医药研发外包服务领域的领先企业，凯莱英在行业重要活动前夕受到资金青睐，其股价在板块普涨的背景下表现尤为突出。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623379186","title":"CXO概念股强势 凯莱英(06821)涨13.85% 机构认为CXO基本面拐点已经出现","url":"https://stock-news.laohu8.com/highlight/detail?id=2623379186","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623379186?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:23","pubTimestamp":1774923794,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO概念股强势，凯莱英(06821)涨13.85%，昭衍新药(06127)涨7.34%，药明生物(02269)涨5.99%，康龙化成(03759)涨4.54%，药明康德(02359)涨4.12%，泰格医药(03347)涨2.89%，金斯瑞生物科技(01548)涨1.09%。浙商医药团队分析指出，在CXO产业持续出清，股价相对低位背景下，看好本土头部CDMO企业和受益国内需求复苏CRO企业底部投资机会。从财务、需求和供给数据分析，该机构认为CXO基本面拐点已经出现，并有望持续复苏。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977810","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","LU0140636845.USD","LU0181495838.USD","BK1589","LU1880383366.USD","IE00B0JY6N72.USD","LU0417516738.SGD","HK0000306701.USD","LU0516422440.USD","03759","LU0819121731.USD","LU0307460666.USD","LU0856984785.SGD","LU0348735423.USD","LU0043850808.USD","BK1576","LU0456827905.SGD","LU1328615791.USD","LU0348825331.USD","03347","LU0516423091.SGD","06821","LU0823426480.USD","LU0051755006.USD","LU1688375341.USD","LU0823426308.USD","LU0516423174.USD","LU0327786744.USD","LU0588546209.SGD","06127","02359","002821","LU0516422366.SGD","LU1046422090.SGD","LU1794554557.SGD","LU1242518857.USD","LU0039217434.USD","LU0572944931.SGD","LU0979878070.USD","LU2045819591.USD","LU0456846285.SGD","BK1521","LU0326950275.SGD","LU0052750758.USD","01548","LU0359201612.USD","LU3063872942.SGD","CXO","LU0320764599.SGD","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109731579","title":"港股异动 | 医药外包概念走强，昭衍新药绩后涨超13%，凯莱英涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109731579","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109731579?lang=zh_cn&edition=full","pubTime":"2026-03-31 09:51","pubTimestamp":1774921897,"startTime":"0","endTime":"0","summary":"3月31日，医药外包概念走强，$昭衍新药(06127)$涨超13%，$凯莱英(06821)$涨超11%，$康龙化成(03759)$涨超6%，$药明生物(02269)$、$泰格医药(03347)$涨超5%","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ee4d118e55b1b421073820cd0cff0613","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1328615791.USD","BK0132","06127","BK1141","BK1515","BK1574","BK0239","BK0216","BK1576","09939","BK4588","BK1161","BK1191","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623373124","title":"【券商聚焦】中信证券：基本医保基金收支和结余整体保持稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2623373124","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623373124?lang=zh_cn&edition=full","pubTime":"2026-03-31 08:59","pubTimestamp":1774918794,"startTime":"0","endTime":"0","summary":"2026年2月医保支出同比增速回升，收支剪刀差有所收窄。该机构预计在医保基金监管力度持续加大，DRG/DIP精细化管理的推动下，2026年全年基金结余率或将延续此前节奏略有提升。医疗健康产业政策改革进入密集期，建议持续关注政策驱动下的医疗健康产业投资机会。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06030","BK1147","BK1100","BK1161","02268","BK1515","LU1115378108.SGD","03933","BK1583","BK1564","IE00B543WZ88.USD","01789","LU0634319403.HKD","LU1328615791.USD","LU1770034418.SGD","BK0276","LU0348783233.USD","BK0012","BK1617","LU1997245177.USD","LU2148510915.USD","BK1588","HK0000165453.HKD","06160","01530","02367","LU0405327494.USD","09688","LU1969619763.USD","LU0348735423.USD","LU2399975544.HKD","600030","BK1593","LU1255011170.USD","LU2495084118.USD","BK1191","LU0348766576.USD","02196","LU2488822045.USD","LU0307460666.USD","LU0405327148.USD","BK0028","01099","09926","LU1303224171.USD","06821","LU1719994722.HKD","02228","IE00BPRC5H50.USD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623341589","title":"凯莱英(06821)发布年度业绩 归母净利润约11.33亿元，同比增加19.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623341589","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623341589?lang=zh_cn&edition=full","pubTime":"2026-03-30 22:51","pubTimestamp":1774882314,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(06821)发布截至2025年12月31日止年度业绩，该集团取得收益约66.70亿元(人民币，下同)，同比增长14.91%;归属于上市公司股东的净利润约11.33亿元，同比增加19.35%;每股基本盈利3.16元。拟派付每10股普通股人民币13.00元(含税)。公告称，公司秉承“做深”大客户，逐步延伸服务链。报告期内，来自大型制药公司收入人民币29.16亿元，同比增长8.36%;公司坚持“做广”中小客户，储备潜力项目。来自中小制药公司收入人民币37.55亿元，同比增长20.57%，收入来源呈现更为多元的趋势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06821","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171887802","title":"凯莱英将于2026年07月24日派发末期股息每股1.30元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171887802","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171887802?lang=zh_cn&edition=full","pubTime":"2026-03-30 22:07","pubTimestamp":1774879668,"startTime":"0","endTime":"0","summary":"凯莱英于2026年3月30日公告，根据截至2025年12月31日止年度的财务结果，公司董事会宣派末期股息每10股13元人民币，折合每股1.30元人民币。该股息尚待于2026年6月10日获得股东大会批准，并计划于2026年7月24日派发。公告显示，股息性质为普通股息，公司预设派发货币为港元，具体汇率及除净日均有待公布。股东如需办理过户登记，需留意香港中央证券登记有限公司相关截止日期，代扣所得税信息亦将另行公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623311483","title":"Schroders PLC增持凯莱英(06821)8.85万股 每股作价约79.03港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623311483","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623311483?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:08","pubTimestamp":1774868890,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，3月26日，Schroders PLC增持凯莱英(06821)8.85万股，每股作价79.0296港元，总金额约为699.41万港元。增持后最新持股数目为562.14万股，持股比例为20.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","LU1328615791.USD","BK0239","002821","EWH","06821","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622074424","title":"凯莱英（002821）披露召开2026年第一次临时股东会等三会通知，3月25日股价上涨0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622074424","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622074424?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:10","pubTimestamp":1774447827,"startTime":"0","endTime":"0","summary":"截至2026年3月25日收盘，凯莱英报收于96.5元，较前一交易日上涨0.95%，最新总市值为348.24亿元。近日，凯莱英医药集团（天津）股份有限公司发布《关于召开2026年第一次临时股东会、2026年第一次A股类别股东会及2026年第一次H股类别股东会的通知》。会议将审议修订董事及高级管理人员薪酬管理制度、回购注销2025年A股限制性股票激励计划部分限制性股票、修订公司章程等议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500043643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002821","BK0239","LU1328615791.USD","BK0132","BK1191","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621095723","title":"【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095723?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516571.SGD","BK1617","BK1207","09688","02367","BK1583","LU0348766576.USD","LU2399975544.HKD","LU0348784397.USD","01099","BK1191","BK1593","09926","LU2488822045.USD","06160","LU0348827113.USD","LU2476274308.USD","LU0348767384.USD","BK1197","01789","LU1303224171.USD","02196","LU2476274720.SGD","LU1794554557.SGD","01530","03329","LU1115378108.SGD","LU1770034418.SGD","BK1141","LU2778985437.USD","BK1500","IE00B543WZ88.USD","LU0417516902.SGD","03933","LU2328871848.SGD","LU0540923850.HKD","LU0307460666.USD","LU0634319403.HKD","02268","BK1585","02228","BK1588","CXO","LU1719994722.HKD","06821","BK1574","LU0417516738.SGD","IE00BPRC5H50.USD","LU0348735423.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619461785","title":"凯莱英（002821）披露董事会会议日期公告，3月16日股价下跌0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619461785","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619461785?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:29","pubTimestamp":1773671358,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，凯莱英报收于99.08元，较前一交易日下跌0.23%，最新总市值为357.55亿元。该股当日开盘98.94元，最高100.74元，最低97.08元，成交额达2.66亿元，换手率为0.85%。近日，凯莱英医药集团（天津）股份有限公司发布H股公告，宣布将于2026年3月30日举行董事会会议，考虑及批准公司及其附属公司截至2025年12月31日止年度业绩的发布，并考虑建议派发末期股息（如有）。公告同时列出了董事会成员名单。本公告由董事长Hao Hong博士代表董事会签署。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600036892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","06821","LU1328615791.USD","002821","BK0132","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619719796","title":"凯莱英(06821)购回及注销部分根据2025年A股计划授予的限制性A股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2619719796","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619719796?lang=zh_cn&edition=full","pubTime":"2026-03-13 20:57","pubTimestamp":1773406667,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(06821)发布公告，于2026年3月13日，本公司董事会审议并通过了“关于购回及注销 2025年A股计划项下部分限制性股份的议案”，据此将购回及注销共计6.1万股由 (i)四名已辞职激励对象根据2025年A股计划首次授予，及(ii)一名已辞职激励对象根据2025年A股计划预留授予项下所持有的已授出但尚未解禁的限制性A股股份(购回及注销事项)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399300","06821","002821","BK0132","159982","BK0239","LU1328615791.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.asymchem.com","stockEarnings":[{"period":"1week","weight":-0.0405},{"period":"1month","weight":0.1708},{"period":"3month","weight":0.1537},{"period":"6month","weight":0.0087},{"period":"1year","weight":1.2115},{"period":"ytd","weight":0.3813}],"compareEarnings":[{"period":"1week","weight":0.0253},{"period":"1month","weight":-0.008},{"period":"3month","weight":-0.0183},{"period":"6month","weight":-0.0205},{"period":"1year","weight":0.2708},{"period":"ytd","weight":0.0048}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"凯莱英医药集团（天津）股份有限公司是一家主要从事提供医药外包一站式综合服务的中国公司。该公司的业务包括小分子药物定制研发生产（CDMO）、化学大分子CDMO、临床研究服务、制剂CDMO、生物大分子CDMO、技术输出和合成生物技术。该公司的产品类别涵盖多肽、寡核苷酸、单克隆抗体、抗体偶联药物和信使RNA等。该公司主要在国内外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.058446},{"month":2,"riseRate":0.4,"avgChangeRate":0.006896},{"month":3,"riseRate":0.4,"avgChangeRate":0.004398},{"month":4,"riseRate":0.6,"avgChangeRate":-0.051669},{"month":5,"riseRate":0.5,"avgChangeRate":0.040294},{"month":6,"riseRate":0.5,"avgChangeRate":0.01751},{"month":7,"riseRate":0.5,"avgChangeRate":0.064856},{"month":8,"riseRate":0.25,"avgChangeRate":-0.064097},{"month":9,"riseRate":0.75,"avgChangeRate":0.16322},{"month":10,"riseRate":0,"avgChangeRate":-0.125554},{"month":11,"riseRate":0.5,"avgChangeRate":0.010602},{"month":12,"riseRate":0.25,"avgChangeRate":-0.010177}],"exchange":"SEHK","name":"凯莱英","nameEN":"ASYMCHEM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯莱英(06821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯莱英,06821,凯莱英股票,凯莱英股票老虎,凯莱英股票老虎国际,凯莱英行情,凯莱英股票行情,凯莱英股价,凯莱英股市,凯莱英股票价格,凯莱英股票交易,凯莱英股票购买,凯莱英股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯莱英(06821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}